Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.58 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.58 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.58 |
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.58 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.58 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.58 |
| ▸ | BDKRB2 known ✓ | P30411 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | APAF1 | O14727 | 3/20 | 0.58 |
| ▸ | USP2 | O75604 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | RAD52 | P43351 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2524643 | 0.95 | SMN1; SMN2 (0.64) | SMN1; SMN2ALDH1A1TDP1HIF1AMEN1 | |
| Hydrochloric Acid SCHEMBL8811192 | 0.84 | SIGMAR1 (0.43) | SMN1; SMN2ALDH1A1TDP1HIF1AMEN1 | |
| Hydrochloric Acid SCHEMBL5060675 | 0.83 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1TDP1HIF1AMEN1 | |
| SCHEMBL9324553 | 0.83 | SIGMAR1 (0.44) | SMN1; SMN2ALDH1A1TDP1HIF1AMEN1 | |
| Hydrochloric Acid SCHEMBL11179545 | 0.81 | SIGMAR1 (0.42) | SMN1; SMN2ALDH1A1TDP1HIF1AMEN1 | |
| Hydrochloric Acid SCHEMBL19409277 | 0.78 | SMN1; SMN2 (0.91) | SMN1; SMN2ALDH1A1TDP1HIF1AMEN1 | |
| SCHEMBL10878637 | 0.76 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1TDP1HIF1AMEN1 | |
| Hydrochloric Acid SCHEMBL2524640 | 0.76 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1TDP1HIF1AMEN1 | |
| Hydrochloric Acid SCHEMBL11423241 | 0.74 | SMN1; SMN2 (0.70) | SMN1; SMN2ALDH1A1TDP1HIF1AMEN1 | |
| SCHEMBL8646229 | 0.74 | DRD2 (0.39) | SMN1; SMN2ALDH1A1MEN1USP2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016010984-A2 | COMPOSITIONS AND METHODS FOR TREATING ROSACEA | TISSUE TECH, INC. (US) | 2016-01-21 | — | — | WO | claimed |
| US-20160008295-A1 | COMPOSITIONS AND METHODS FOR TREATING ROSACEA | TISSUE TECH, INC. | 2016-01-14 | — | — | US | claimed |
| US-4615807-A | QUATERNARY AMMONIUM SALTS AND ORGANOTIN MIXTURE TO DISINFECT | UNITED STATES ENVIRONMENTAL RESOURCES, CORP. (US) | 1986-10-07 | — | — | US | claimed |
| US-10155788-B2 | Cationic steroidal antimicrobial prodrug compositions and uses thereof | BRIGHAM YOUNG UNIVERSITY (US) | 2018-12-18 | — | — | US | disclosed |
| US-9827195-B2 | Fatty acid pharmaceutical foam | STIEFEL RESEARCH AUSTRALIA PTY LTD (AU) | 2017-11-28 | — | — | US | disclosed |
| US-20160096864-A1 | CATIONIC STEROIDAL ANTIMICROBIAL PRODRUG COMPOSITIONS AND USES THEREOF | BRIGHAM YOUNG UNIVERSITY (US) | 2016-04-07 | — | — | US | disclosed |
| WO-2016010984-A2 | COMPOSITIONS AND METHODS FOR TREATING ROSACEA | TISSUE TECH, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| US-20160008295-A1 | COMPOSITIONS AND METHODS FOR TREATING ROSACEA | TISSUE TECH, INC. | 2016-01-14 | — | — | US | disclosed |
| US-20150209280-A1 | FATTY ACID PHARMACEUTICAL FOAM | STIEFEL RES AUSTRALIA PTY LTD (AU) | 2015-07-30 | — | — | US | disclosed |
| US-9023863-B2 | Fatty acid pharmaceutical foam | STIEFEL RESEARCH AUSTRALIA PTY LTD (AU) | 2015-05-05 | — | — | US | disclosed |
| EP-2046121-B1 | FATTY ACID PHARMACEUTICAL FOAM | STIEFEL RES AUSTRALIA PTY LTD (AU) | 2012-08-22 | — | — | EP | disclosed |
| US-7186416-B2 | Foamable pharmaceutical compositions and methods for treating a disorder | STIEFEL LABORATORIES, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1633368-A2 | FOAMABLE PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING A DISORDER | STIEFEL LABORATORIES, INC. (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050232957-A1 | Compositions and methods for moisturizing skin | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE | 2005-10-20 | — | — | US | disclosed |
| WO-2004105702-A2 | FOAMABLE PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING A DISORDER | STIEFEL LABORATORIES, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040241099-A1 | Foamable pharmaceutical compositions and methods for treating a disorder | CONNETICS CORPORATION | 2004-12-02 | — | — | US | disclosed |
| US-20040120990-A1 | Absorbent proteins and methods for using same | CUSHMAN JOHN C (US) | 2004-06-24 | — | — | US | disclosed |
| US-6547063-B1 | Article for the delivery of foam products | THE PROCTER & GAMBLE COMPANY | 2003-04-15 | — | — | US | disclosed |
| US-6283336-B1 | Article for the delivery of foam products | THE PROCTER & GAMBLE COMPANY | 2001-09-04 | — | — | US | disclosed |
| US-4615807-A | QUATERNARY AMMONIUM SALTS AND ORGANOTIN MIXTURE TO DISINFECT | UNITED STATES ENVIRONMENTAL RESOURCES, CORP. (US) | 1986-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150209280-A1 | FATTY ACID PHARMACEUTICAL FOAM | FASN, FFAR3, FFAR1 | CHRM2 4549/4885CHRM1 4673/4885CHRM3 4532/4885 |
| US-10155788-B2 | Cationic steroidal antimicrobial prodrug compositions and uses thereof | CYP21A2, CYP11B1, CYP11B2 | CHRM2 3937/4885CHRM1 2939/4885CHRM3 3455/4885 |
| US-20160096864-A1 | CATIONIC STEROIDAL ANTIMICROBIAL PRODRUG COMPOSITIONS AND USES THEREOF | CYP21A2, CYP11B1, CYP11B2 | CHRM2 3937/4885CHRM1 2939/4885CHRM3 3455/4885 |
| US-20040241099-A1 | Foamable pharmaceutical compositions and methods for treating a disorder | CLN6, CYP27A1, CYP46A1 | CHRM2 4262/4885CHRM1 4737/4885CHRM3 4432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.